
    
      This prospective, randomized, double-blind, placebo-controlled release study will enroll
      approximately 300 healthy adults 18 to 49 years of age. Eligible participants will be
      randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo
      by intranasal spray. Randomization will be stratified by site. This study will be conducted
      at 3 sites in the United States of America. Each participant will receive 1 dose of
      investigational product on Day 1. The duration of study participation for each participant is
      the time from study vaccination through 181 days after study vaccination.
    
  